Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
This article was originally published in PharmAsia News
Executive Summary
Just days after the publication of promising data concerning its antibiotic drug candidate fidaxomicin, Optimer Pharmaceuticals Inc. has licensed the compound to Astellas Pharma Europe Ltd. to treat Clostridium difficile infections in Europe and additional territories